GenePeeks names new chair
This article was originally published in Scrip
Lifeprint Group, the parent company for GenePeeks – a genetic information company focused on next-generation disease risk analysis – has named Mara Aspinall executive chair of its board of directors. Ms Aspinall is the former president and CEO of Ventana Medical Systems. Vertana is a member of the Roche Group and a leader in the development, manufacture and commercialization of tissue-based cancer diagnostics that enable the delivery of personalized healthcare to patients. Previously, Ms Aspinall spent 12 years with Genzyme, where she held leadership roles that included president of Genzyme Genetics and president of Genzyme Pharmaceuticals.
You may also be interested in...
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.
Experts discuss the future of brain health, changing the stereotypical view of an Alzheimer’s patient and how technology and science have evolved the treatment possibilities for dementia patients in 2020 – even if ‘clinical practice is taking a long time to catch up.’
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.